Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Leticia, Sarasa"'
Autor:
María Pascual-Lucas, José Antonio Allué, Leticia Sarasa, Noelia Fandos, Sergio Castillo, Jose Terencio, Manuel Sarasa, Juan Pablo Tartari, Ángela Sanabria, Lluís Tárraga, Agustín Ruíz, Marta Marquié, Sang Won Seo, Hyemin Jang, Mercè Boada, on behalf of the FACEHBI study group
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-14 (2023)
Abstract Background Accessible and cost-effective diagnostic tools are urgently needed to accurately quantify blood biomarkers to support early diagnosis of Alzheimer’s disease (AD). In this study, we investigated the ability of plasma amyloid-beta
Externí odkaz:
https://doaj.org/article/915cd5fe115a4bbc9425e48fab2f58e0
Autor:
José Antonio Allué, María Pascual‐Lucas, Leticia Sarasa, Sergio Castillo, Manuel Sarasa, María Eugenia Sáez, Sara Abdel‐Latif, Robert A. Rissman, Jose Terencio
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 15, Iss 2, Pp n/a-n/a (2023)
Abstract INTRODUCTION This study explored the ability of plasma amyloid beta (Aβ)42/Aβ40 to identify brain amyloid deposition in cognitively unimpaired (CU) individuals. METHODS Plasma Aβ was quantified with an antibody‐free high‐performance l
Externí odkaz:
https://doaj.org/article/f6f71086b2534208804e01fb343b1074
Autor:
Min Young Chun, Hyemin Jang, Hee Jin Kim, Jun Pyo Kim, John Gallacher, José Antonio Allué, Leticia Sarasa, Sergio Castillo, María Pascual-Lucas, Duk L. Na, Sang Won Seo, on behalf of DPUK
Publikováno v:
Frontiers in Aging Neuroscience, Vol 15 (2023)
BackgroundEarly detection of β-amyloid (Aβ) accumulation, a major biomarker for Alzheimer’s disease (AD), has become important. As fluid biomarkers, the accuracy of cerebrospinal fluid (CSF) Aβ for predicting Aβ deposition on positron emission
Externí odkaz:
https://doaj.org/article/747188cd7d9b4adb8a0ffc5b9f630f1a
Autor:
Hyemin Jang, Ji Sun Kim, Hye Joo Lee, Chi-Hun Kim, Duk L. Na, Hee Jin Kim, José Antonio Allué, Leticia Sarasa, Sergio Castillo, Pedro Pesini, John Gallacher, Sang Won Seo, on behalf of DPUK
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-13 (2021)
Abstract Background We assessed the feasibility of plasma Aβ42/Aβ40 determined using a novel liquid chromatography-mass spectrometry method (LC-MS) as a useful biomarker of PET status in a Korean cohort from the DPUK Study. Methods A total of 580 p
Externí odkaz:
https://doaj.org/article/d74c332c41954d569a82cfd39407f8ed
Autor:
Virginia Pérez-Grijalba, Javier Arbizu, Judith Romero, Elena Prieto, Pedro Pesini, Leticia Sarasa, Fernando Guillen, Inmaculada Monleón, Itziar San-José, Pablo Martínez-Lage, Josep Munuera, Isabel Hernández, Mar Buendía, Oscar Sotolongo-Grau, Montserrat Alegret, Agustín Ruiz, Lluis Tárraga, Mercè Boada, Manuel Sarasa, The AB255 Study Group
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-9 (2019)
Abstract Background To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-
Externí odkaz:
https://doaj.org/article/8ea557f727a645db9b4c9c8e9f242844
Autor:
Josef Pannee, Leslie M. Shaw, Magdalena Korecka, Teresa Waligorska, Charlotte E. Teunissen, Erik Stoops, Hugo M. J. Vanderstichele, Kimberley Mauroo, Inge M. W. Verberk, Ashvini Keshavan, Pedro Pesini, Leticia Sarasa, Maria Pascual‐Lucas, Noelia Fandos, José‐Antonio Allué, Erik Portelius, Ulf Andreasson, Ritsuko Yoda, Akinori Nakamura, Naoki Kaneko, Shieh‐Yueh Yang, Huei‐Chun Liu, Stefan Palme, Tobias Bittner, Kwasi G. Mawuenyega, Vitaliy Ovod, James Bollinger, Randall J. Bateman, Yan Li, Jeffrey L. Dage, Erik Stomrud, Oskar Hansson, Jonathan M. Schott, Kaj Blennow, Henrik Zetterberg
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 13, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction Blood‐based assays to measure brain amyloid beta (Aβ) deposition are an attractive alternative to the cerebrospinal fluid (CSF)–based assays currently used in clinical settings. In this study, we examined different blood‐
Externí odkaz:
https://doaj.org/article/07cf8801f7b140a6a12154efbdfca507
Autor:
Ana-María Lacosta, María Pascual-Lucas, Pedro Pesini, Diego Casabona, Virginia Pérez-Grijalba, Iván Marcos-Campos, Leticia Sarasa, Jesus Canudas, Hassnae Badi, Inmaculada Monleón, Itziar San-José, Josep Munuera, Octavio Rodríguez-Gómez, Carla Abdelnour, Asunción Lafuente, Mar Buendía, Mercè Boada, Lluis Tárraga, Agustín Ruiz, Manuel Sarasa
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-13 (2018)
Abstract Background Immunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer’s disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be effective to date. W
Externí odkaz:
https://doaj.org/article/1030c599a5ae4b4d8f002a265d9af497
Autor:
Elisabet Molina, Sergio Castillo, Ana M Lacosta, Jose A Allué, Noelia Fandos, María Montañés, Judith Romero, Leticia Sarasa, Mercè Boada, Manuel Sarasa
Publikováno v:
Alzheimer's & Dementia. 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46d3e7d697956fe215464897a05252c6
https://doi.org/10.1002/alz.065633
https://doi.org/10.1002/alz.065633
Autor:
María, Pascual-Lucas, José Antonio, Allué, Leticia, Sarasa, Noelia, Fandos, Sergio, Castillo, Jose, Terencio, Manuel, Sarasa, Juan Pablo, Tartari, Ángela, Sanabria, Lluís, Tárraga, Agustín, Ruíz, Marta, Marquié, Sang Won, Seo, Hyemin, Jang, Mercè, Boada, A, Vivas
Publikováno v:
Alzheimer's researchtherapyReferences. 15(1)
Accessible and cost-effective diagnostic tools are urgently needed to accurately quantify blood biomarkers to support early diagnosis of Alzheimer's disease (AD). In this study, we investigated the ability of plasma amyloid-beta (Aβ)42/Aβ40 ratio m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fe44c84f7fff016d8eb827b49a9356d7
https://pubmed.ncbi.nlm.nih.gov/36604729
https://pubmed.ncbi.nlm.nih.gov/36604729
Autor:
Shorena Janelidze, Kaj Blennow, Leticia Sarasa, Henrik Zetterberg, Pedro Pesini, Oskar Hansson, Nicholas K. Proctor, Antoine Leuzy, Nicholas C. Cullen, Niklas Mattsson-Carlgren, Jeffrey L. Dage, Erik Stomrud, José Antonio Allué, Sebastian Palmqvist
Publikováno v:
Nature Aging. 1:114-123
We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI) using plasma biomarkers of β-amyloid (Aβ), tau and neurodegeneration. A total of 573 patients with MCI from the Swedish BioFINDER study a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::207885cf76e4dc2bc833bd2c070da077
https://doi.org/10.1038/s43587-020-00003-5
https://doi.org/10.1038/s43587-020-00003-5